Abstract
Objective: Despite advancements in ovarian cancer (OC) therapy, the largest impact for improving OC mortality lies within the discovery of screening tests that detect early-stage disease or identify patients at risk for developing OC. The objective of this study was to develop a cell-free DNA (cfDNA) molecular signature to detect OC utilizing site-specific collection of cervicovaginal fluids (CVF).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
